公司消息– SyneuRx | 美容美髮公開資訊

心悅生醫治療難治型憂鬱症及其自殺症狀新藥獲美國FDA核准執行第二期人體臨床試驗.2021-03-08.心悅生醫兩項治療精神分裂症新藥獲台灣衛福部核准執行第二(b)/三期人體 ...

November 19, 2021 – Los Angeles, CA – SyneuRx™ International, (www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today announced that its investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate Pentarlandir® has successfully been in Phase II US-FDA trial for several months and is nearing Phase III in 2022.

Designed as an early-stage COVID-19 treatment, Pentarlandir® is given by mouth to patients suffering either from ‘breakthrough’ cases of COVID-19 (for those who have been previously vaccinated or infected) or potentially as a first-line treatment pathway for the unvaccinated who might otherwise face potential hospitalization and death. SyneuRx has previously received ‘Breakthrough Therapy Designation and Orphan Drug Designation’ grants by the FDA for its CNS drug candidates.

Pentarlandir® is based on highly-purified...